Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fesomersen - Ionis Pharmaceuticals

Next Previous
Drug Profile

Fesomersen - Ionis Pharmaceuticals

Alternative Names: BAY-2976217; Factor XI LICA; ION-957943; IONIS-FXI-LRX

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Amides; Amino sugars; Anticoagulants; Antisense elements; Antisense oligonucleotides; Antithrombotics; Drug conjugates
  • Mechanism of Action Factor XI expression modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Phase II Thrombosis

Most Recent Events

  • 04 Nov 2022 Updated efficacy data from a phase II RE-THINc ESRD presented at the American Society of Nephrology's Kidney Week (ASN-2022)
  • 28 Jul 2022 Efficacy and adverse events data from phase II RE-THINC ESRD trial for Thrombosis released by Ionis
  • 12 May 2022 Ionis Pharmaceuticals completes the phase II RE-THINC ESRD trial for Thrombosis in Greece, Czech Republic, Belgium, Bulgaria, Canada, Germany, Hungary, Japan, Latvia, Russia, Spain, South Korea, Taiwan, Ukraine, USA (EudraCT2019-003927-39) (NCT04534114)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top